Brain Cancer Trial, Recruiting NCT05326334 Sponsor: Ottawa Hospital Research Institute Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT05326334
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with a specific type of aggressive brain tumour called glioblastoma (WHO grade 4, IDH-1 R132H wild type)
  • People who have had surgery that removed at least 70% of the tumour
  • People aged 18 or older
  • People who are generally able to carry out daily activities with little to no limitation, or those with moderate limitation who are taking a low dose (8 mg/day or less) of a steroid medication called dexamethasone
  • People who are planned to receive a standard course of radiotherapy (60 Gy in 30 sessions) combined with a chemotherapy drug called temozolomide, starting within 12 weeks of surgery
  • People who are able to give written consent themselves, or who have a legal substitute decision-maker who can do so on their behalf

Who may not be able to join:

  • People who have another cancer that has spread or a second cancer that could affect how the study results are interpreted
  • People who are receiving any additional treatments for glioblastoma beyond the standard course of temozolomide and radiotherapy followed by up to 6 cycles of adjuvant temozolomide (confirm with trial site for specific details)
  • People who are unable to provide stool (bowel) samples for the study
  • People who have any other diagnosis or medical or psychological condition that the trial investigator considers would make participation unsuitable

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 613-737-7700

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ottawa Hospital Research Institute
Registry
ClinicalTrials.gov
Start date
2 March 2023
Est. completion
1 July 2025

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Feasibility of collecting stool samples; Feasibility of participant enrollment; Feasibility of stool sample analysis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov